CYTX - The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers
Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue growth from these small companies against the probability of getting there and the resiliency of these companies to avoid or overcome damaging dilution before they reach the finish line. For those not familiar with the sector, there are many variations of regenerative/stem cell therapies. Prior to discussing discuss the subject of this